Meta-analysis has shown that immunohistochemical p53 expression in both patients with UC and dysplasia (compared to patients with UC and without dysplasia; n = 297 vs. 335, OR 10.76, 95% CI 4.63–25.03, p < 0.001) and no dysplasia (compared to normal tissue; n = 233 vs. 130, OR 3.14, 95% CI 1.58–6.24, p = 0.001) was closely associated with CA-CRC progression [126]. This evidence concerns the gene TP53 and cancer.